RxDoctor Payments Data

Mahish Joshi, MD

Internal Medicine · Austintown, OHNPI 1952384679

Payments from drug & device makers

$5,961in general payments, 2019–2025

Across 407 payments — averaging $14.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$753
  • AstraZeneca$697
  • Johnson & Johnson$618
  • AbbVie$603
  • Novo Nordisk$509
  • Lilly USA, LLC$482
  • plus $2K from 24 others

What the payments were for

  • Food & beverage$5,956100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,961 in reported general payments places this provider in the 90th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$50,106
Medicare patients
122
Services billed
663

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban164$129,265
OzempicSemaglutide70$75,497
TrulicityDulaglutide35$61,363
JardianceEmpagliflozin67$60,334
XareltoRivaroxaban49$44,266
JanuviaSitagliptin Phosphate41$33,249
LinzessLinaclotide16$20,480
FarxigaDapagliflozin Propanediol27$20,161
Repatha SureclickEvolocumab20$13,259
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$12,611
Bydureon BciseExenatide Microspheres12$9,844
TrulancePlecanatide12$7,905
Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro11$5,851
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen296$5,556
Levothyroxine Sodium372$4,006

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$424$132,232176 claims
Novo NordiskOzempic$509$75,49770 claims
Lilly USA, LLCTrulicity$482$61,36335 claims
Boehringer IngelheimJardiance$753$60,33467 claims
Johnson & JohnsonXarelto$618$44,26649 claims
MerckJanuvia$135$33,24941 claims
AstraZenecaFarxiga, Breztri Aerosphere$697$32,77245 claims
AbbVieLinzess, Synthroid$603$22,12766 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$349$7,90512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Austintown

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →